Sleep Apnea Significantly Impacts Mortality Benefit of GLP-1s

Dr. Cosmo Fowler explains thet data revealed one-year mortality in patients with type 2 diabetes prescribed GLP-1 RAs was substantially lower than those not prescribed the drugs, and disproportionate benefit for those also diagnosed with OSA. The results were presented at the American College of Chest Physicians (CHEST) 2025 Annual Meeting.

Ensifentrine treatment improves COPD symptoms and quality of life in a pooled analysis of the ENHANCE trials

Professor Nicola Hanania discuss the lessons from the ENHANCE trials were presented at the American College of Chest Physicians (CHEST) 2025 Annual Meeting.

Comparative Cardioprotective Effects of GLP-1 Receptor Agonists versus SGLT2 Inhibitors in Pulmonary Arterial Hypertension: Insights from a Large-Scale Real-World data analysis

Dr. Saud Alawad and Prof. Sunil Sharma discuss the comparative cardioprotective effects of GLP-1 receptor agonists versus SGLT2 inhibitors in pulmonary arterial hypertension after the American College of Chest Physicians (CHEST) 2025 Annual Meeting.